Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MECCA: Metronomic Capecitabine + Aromatase Inhibitor in 1L HR+/HER2- Metastatic Breast Cancer
NCT02767661Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2017
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Sun Yat-sen University. Started Jul 2017; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02767661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767661.